SG11202101441SA - Tetrahydropyridopyrimidine derivatives as ahr modulators - Google Patents

Tetrahydropyridopyrimidine derivatives as ahr modulators

Info

Publication number
SG11202101441SA
SG11202101441SA SG11202101441SA SG11202101441SA SG11202101441SA SG 11202101441S A SG11202101441S A SG 11202101441SA SG 11202101441S A SG11202101441S A SG 11202101441SA SG 11202101441S A SG11202101441S A SG 11202101441SA SG 11202101441S A SG11202101441S A SG 11202101441SA
Authority
SG
Singapore
Prior art keywords
indol
compound according
ethyl
nmr
ppm
Prior art date
Application number
SG11202101441SA
Other languages
English (en)
Inventor
Antonio Mete
James Hitchin
Mark Graham
John King-Underwood
Philip Thorne
Original Assignee
Jaguahr Therapeutics Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jaguahr Therapeutics Pte Ltd filed Critical Jaguahr Therapeutics Pte Ltd
Publication of SG11202101441SA publication Critical patent/SG11202101441SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11202101441SA 2018-08-24 2019-08-23 Tetrahydropyridopyrimidine derivatives as ahr modulators SG11202101441SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201807244X 2018-08-24
PCT/EP2019/072641 WO2020039093A1 (en) 2018-08-24 2019-08-23 Tetrahydropyridopyrimidine derivatives as ahr modulators

Publications (1)

Publication Number Publication Date
SG11202101441SA true SG11202101441SA (en) 2021-03-30

Family

ID=67982013

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101441SA SG11202101441SA (en) 2018-08-24 2019-08-23 Tetrahydropyridopyrimidine derivatives as ahr modulators

Country Status (14)

Country Link
US (1) US12221439B2 (cg-RX-API-DMAC7.html)
EP (1) EP3841102B1 (cg-RX-API-DMAC7.html)
JP (1) JP2021535213A (cg-RX-API-DMAC7.html)
KR (1) KR20210049135A (cg-RX-API-DMAC7.html)
CN (1) CN112739698A (cg-RX-API-DMAC7.html)
AU (1) AU2019323714A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021003529A2 (cg-RX-API-DMAC7.html)
CA (1) CA3110402A1 (cg-RX-API-DMAC7.html)
IL (1) IL281023A (cg-RX-API-DMAC7.html)
MX (1) MX2021002215A (cg-RX-API-DMAC7.html)
PH (1) PH12021550382A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101441SA (cg-RX-API-DMAC7.html)
WO (1) WO2020039093A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202100931B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3715471A1 (en) 2019-03-29 2020-09-30 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Ahr signature marker set
EP3721894A1 (en) 2019-04-10 2020-10-14 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) as a biomarker and uses thereof
EP3835432A1 (en) 2019-12-10 2021-06-16 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) and respective metabolites as biomarkers for cancer
JP2023515128A (ja) 2020-02-26 2023-04-12 ジャガー セラピューティクス ピーティーイーリミテッド Ahrシグナル伝達の調節に有用なピリドピリミジン誘導体
MX2022012739A (es) * 2020-04-17 2022-11-07 Dong A St Co Ltd Derivados de piridopirimidinona y su uso como moduladores del receptor de hidrocarburos de arilo.
CN114369097B (zh) * 2020-10-15 2023-07-14 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
WO2023033741A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
WO2023033742A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
CN119948035A (zh) 2022-10-03 2025-05-06 捷豹治疗有限公司 可用于调节AhR信号传导的化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
AU2001290912A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1663994B1 (en) * 2003-08-05 2012-03-07 Vertex Pharmaceuticals Incorporated Tetrahydroquinazoline compounds as inhibitors of voltage-gated ion channels
WO2006044762A2 (en) * 2004-10-15 2006-04-27 Bayer Pharmaceuticals Corporation Tetrahydro-5h-pyrimido[4,5-d]azepine derivatives useful for the treatment of diseases associated with the 5-ht2c receptor
BRPI0920707A2 (pt) 2008-10-02 2015-12-29 Respivert Ltd compostos
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
US8691827B2 (en) 2009-08-17 2014-04-08 Merck Sharp & Dohme Corp. Amino tetrahydro-pyridopyrimidine PDE10 inhibitors
US10314810B2 (en) 2010-07-27 2019-06-11 Trustees Of Boston University Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics
WO2016154110A1 (en) * 2015-03-20 2016-09-29 Cleave Biosciences, Inc. Companion diagnostic for p97 inhibitor therapy and methods of use thereof
SG11201810366WA (en) 2016-05-25 2018-12-28 Bayer Pharma AG 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
JP2023515128A (ja) 2020-02-26 2023-04-12 ジャガー セラピューティクス ピーティーイーリミテッド Ahrシグナル伝達の調節に有用なピリドピリミジン誘導体

Also Published As

Publication number Publication date
US20210332041A1 (en) 2021-10-28
US12221439B2 (en) 2025-02-11
CA3110402A1 (en) 2020-02-27
BR112021003529A2 (pt) 2021-05-18
KR20210049135A (ko) 2021-05-04
CN112739698A (zh) 2021-04-30
IL281023A (en) 2021-04-29
MX2021002215A (es) 2021-07-15
ZA202100931B (en) 2021-10-27
EP3841102B1 (en) 2022-09-14
WO2020039093A1 (en) 2020-02-27
AU2019323714A1 (en) 2021-03-25
JP2021535213A (ja) 2021-12-16
EP3841102A1 (en) 2021-06-30
PH12021550382A1 (en) 2021-12-13

Similar Documents

Publication Publication Date Title
IL292156A (en) Transduced azacils as trmp8 modulators
ZA201906104B (en) Substituted imidazo-quinolines as nlrp3 modulators
IL281023A (en) Tetrahydropyridopyrimidine derivatives as AHR modulators
IL290153A (en) Tetrahydroquinolinone compounds are installed such as gamma modulators
PL3743406T3 (pl) Modulatory tmem16a
GB2596231B (en) Modulators
IL283990A (en) Modified oxopyridine derivatives
DK3749669T3 (da) Ahr-modulatorer
SG11202101499UA (en) Heterocyclic compounds as ahr modulators
GB201704739D0 (en) Optical modulator
SG11202012594RA (en) Spirochromane derivatives
SI3796975T1 (sl) Derivati sulfonilaminobenzamida
GB2585587B (en) Modulators
HUE062256T2 (hu) Dihidrokromén-származékok
HK40042159A (zh) Ahr调节剂
GB201806948D0 (en) Derivatives
GB2571429B (en) Optical modulator
GB201810495D0 (en) High intensity